This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
Close
Close
Close
Close
Close
Close

Theramex News

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Get in touch

Close

Careers

27 September 2021

Theramex supports World Contraception Day as it continues to champion women’s rights to effective and reliable birth control

World Contraception Day, 26th September 2021

Theramex, a global women’s health company, recognises effective and reliable birth-control as a fundamental aspect of women’s health choices, and is proud to support World Contraception Day’s mission to educate and empower women.

Having control over when to conceive is deemed essential to a women’s wellbeing.1 However, before the COVID-19 pandemic, up to half of pregnancies around the world were unintended, and the UN predicts there could be 7 million more unplanned pregnancies because of the crisis.2,3

Events such as World Contraception Day held annually in September spotlight the importance of equipping all women with sufficient information about the different contraceptives available and their right to access such services, so that they can make an informed choice about their reproductive health.

Theramex CEO Robert Stewart said: “World Contraception Day is an excellent opportunity to highlight that access to effective birth-control is a fundamental right for women. At Theramex, we have more than 400 employees across 80 countries who are dedicated to improving women’s health every day. We are harnessing that commitment and expertise to change the contraception landscape.”

References

  1. Rowe H et al. Aust N Z J Public Health 2016; 40(2):104-9.
  2. Nanda K et al. Glob Health Sci Pract 2020 Jun 30;8(2):166-168.
  3. Cousins S. Lancet 2020; 396(10247): 301-2.

29 September 2021

Theramex now has approval for Bijuva® / Bijuve® combined hormone therapy treatment for post-menopausal women*

Read more

31 August 2021

Real-world evidence demonstrates significant difference in fracture risk reduction for osteoporosis patients using gastro-resistant risedronate (Actonel® GR*) when compared with those using alendronate IR oral bisphosphonate

Read more